IDO1 and COVID-19: In COVID-19 patients, other authors observed increased activity of the TRYCAT pathway60,61, as manifested by decreased tryptophan concentration and increased levels of KN and NFK, resulting from increased IDO activity under the influence of pro-inflammatory cytokines.